Remibrutinib

Novartis · LOU064

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 3 trial completes
Trials
21 active
35 in total · 19 in the EU
Targets
—
None known yet

What this is

How it works
BTK inhibitor
How it’s given
“Remibrutinib film coated tablets in the respective dose strength of the parent study.”In the company’s words, NCT07456891 on ClinicalTrials.gov
Tested for
Chronic Spontaneous Urticaria (4 trials), Hidradenitis Suppurativa (4 trials), Relapsing Multiple Sclerosis (3 trials), Chronic Pruritus of Unknown Origin (2 trials), Chronic Inducible Urticaria, Chronic Spontaneous Urticaria (CSU), Generalized Myasthenia Gravis, IgE-Mediated Food Allergy and 7 more
Main trialPhase 3
“The purpose of this extension study is to collect long-term efficacy, safety and tolerability data on remibrutinib in a selected group of participants with Chronic Spontaneous Urticaria (CSU) who previously completed the treatment phase of remibrutinib preceding Phase 3 core studies. This study will also fulfill the Novartis commitment to provide post-trial access to participants who have completed the preceding Phase 3 studies, where applicable.”In the company’s words, NCT05513001 on ClinicalTrials.gov
Other names
LOU064 · Rhapsido

Other drugs for Chronic Spontaneous Urticaria

All 23 drugs for Chronic Spontaneous Urticaria

Coming up12

Changes2

Last 90 days

FDA approvals1

Trials35

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 26 Aug 2024 An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib
Phase 3Active, not recruiting 17 Sep 2025 Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.
Phase 3Active, not recruiting 11 May 2026 A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines
Phase 3Active, not recruiting 21 Jul 2026 Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)
Phase 3Active, not recruiting 22 Jul 2026 Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
Phase 3Active, not recruiting 3 Nov 2026 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up
Phase 3Active, not recruiting 22 Feb 2027 A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines
Phase 3Active, not recruiting 17 May 2027 A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
Phase 3Active, not recruiting 3 Jun 2027 A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
Phase 3Active, not recruiting 25 Feb 2028 A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
Phase 3Recruiting 24 May 2028 Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Within 24 Weeks
Phase 3Recruiting 26 Feb 2029 A Study to Evaluate Efficacy, Safety, and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)
Phase 3Recruiting 30 Mar 2029 A 52-week Study of Remibrutinib in IgE-mediated Food Allergy
Phase 3Recruiting 25 Jul 2029 Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
Phase 3Recruiting 19 Dec 2029 A Study to Evaluate Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)
Phase 3Recruiting 3 Dec 2030 A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
Phase 3Recruiting 15 Oct 2031 An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS
Phase 3Recruiting 30 Jan 2033 Remibrutinib Open Label Roll-over Post-trial Access Protocol
Phase 2Recruiting 23 Aug 2027 Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria
Phase 2Recruiting 7 Dec 2027 A Phase 2 Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Patients With Papulopustular Rosacea (PPR)
Phase 1Recruiting 29 Nov 2027 A Study to Explore the Tissue Level Effects of Remibrutinib in Adults With Moderate to Severe HS
Phase 3Completed 8 Dec 2023 A Safety and Efficacy Study of Remibrutinib in the Treatment of CSU in Japanese Adults Inadequately Controlled by H1-antihistamines
Phase 3Completed 18 Dec 2023 A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1-antihistamines
Phase 3Completed 27 Dec 2023 A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1 Antihistamines
Phase 3Completed 25 Apr 2024 A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Treated With Remibrutinib up to 12 Weeks.
Phase 2Terminated 27 Apr 2020 Study of Efficacy and Safety of LOU064 in Inadequately Controlled Asthma Patients
Phase 2Completed 14 Jan 2021 This Was a Dose-finding Study to Evaluate Efficacy and Safety of LOU064 in Patients With CSU Inadequately Controlled by H1-antihistamines
Phase 2Terminated 23 Nov 2021 A Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren's Syndrome
Phase 2Completed 9 Sep 2022 An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of LOU064 in Subjects With CSU
Phase 2Completed 4 Dec 2024 Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa
Phase 2Completed 11 Mar 2025 Study of Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With an Allergy to Peanuts
Phase 1Completed 27 Jan 2020 Single Dose and Multiple Dose Study to Assess Safety and Tolerability of LOU064
Phase 1Completed 14 Dec 2023 A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Hepatic Impairment Compared With Matched Healthy Participants
Phase 1Completed 12 Oct 2025 A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Severe Renal Impairment Compared to Matched Healthy Participants.
Phase 1Ended not given A Phase 1, participant blinded, randomized, placebo-controlled study to investigate the remibrutinib exposure in CSF (cerebrospinal fluid) in healthy participants
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Remibrutinib

Following is part of Solo: you see every change to Remibrutinib the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in